The global biologics market was valued at USD 303.95 billion in 2020, growing at a CAGR of 9.59% during the forecast period from 2021 to 2026, in order to reach USD 525.84 billion by 2026. The biologics market is witnessing a positive market growth owing to the factors such as the rising prevalence of autoimmune disorders such as rheumatoid arthritis, the rising prevalence of cancers, the increasing prevalence of infectious diseases, the increasing cases of genetic disorders, and increasing product development activities with the latest innovation with respect to biologics among others.
Some of the Global Biologics Companies with various stages of development include GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, Genentech, Inc, Biogen, bluebird bio, Inc, Janssen Global Services, Cellitron Group and others are currently dominating the Biologics Market.
DelveInsight’s “Biologics Market Insights and Forecast” report provides the current and forecasted Biologics Market trends for the next five years, upcoming innovations in the devices, individual Biologics market share, challenges, drivers, and barriers, and key competitors in the domain.
Biologics: An Overview
Biologics are products that are produced from living organisms or contain components of living organisms. There are several types of biologics drugs which include blood, blood components, vaccines, cells, genes, allergens, tissues, and recombinant proteins. Biologics holds a lot of potential in many therapeutic areas such as cancer treatment, rare diseases, and other severe illnesses which have been difficult to treat using conventional small molecule drugs.
Are you interested to know how the Biologics Market will be growing by 2026? If yes, click to get a snapshot of the Biologics Drugs
Recent Breakthroughs in the Biologics Market
In recent years, the Biologics market observed expansions in terms of clinical, commercial, and clinical development.
- On October 15, 2021, the US FDA approved atezolizumab (Tecentriq) by Genentech, Inc. for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non-small cell lung cancer (NSCLC).
- In August 2021, Bristol Myers Squibbs received conditional marketing authorization for Abecma (idecabtagene vicleucel) by the European Commission for the treatment of adult patients with relapsed and refractory multiple myeloma. It is a first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
- In June 2021, the US FDA approved the product approval of Biogen Inc’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease in an accelerated approval pathway.
According to DelveInsight, the Biologics Clinical Development market would rise rapidly throughout the forecast period due to continuous commercial and clinical development.
Key Players Proactively working in the Biologics Market Insights
In the global market for Biologics key players contribute significantly to their development and are also active in mergers and acquisitions to strengthen their market position.
Some of the Biologics market companies operating actively in the Biologics included GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novo Nordisk, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb, Regeneron Pharmaceuticals Inc., Gilead Sciences, Inc., Boehringer Ingelheim International GmbH, Genentech, Inc, Biogen, bluebird bio, Inc, Janssen Global Services LLC, Cellitron Group, and several others.
Learn more about the Biologics, and get in-depth information @ List of Biologics
COVID19 Impact Analysis on Biologics Market
The biologics market was one of the few domains that exhibited positive growth during the COVID-19 pandemic. Even though lockdown restrictions severely affected production capacities in various industries across the globe, the urgency of developing vaccines for the SARS-CoV-2 virus presented huge growth opportunities for the players operating in biopharmaceutical manufacturing. With the development and the emergency authorization of the first COVID-19 vaccine (the Pfizer-BioNTech COVID-19 Vaccine) in late December 2020, the development and approvals of such vaccines picked up pace across the globe. This led to numerous collaborations and partnerships among pharmaceutical companies and contract manufacturing organizations in order to meet the global supply of these vaccines in a short span of time, which presented a positive outlook for the biologics market despite the disruption of supply chains among other factors.
Request a snapshot of the report, just a click here to know @ Types of Biologics
Scope of the Biologics Market Report
- Study Period: 2019-2027
- Geography Covered: North America, Europe, Asia-Pacific, Rest of the World (Middle East, Africa, and South America)
- Key Biologics Companies: GlaxoSmithKline (NYSE: GSK), Eli Lilly Company (NYSE: LLY), F. Hoffmann-La Roche Ltd (NYSE: RHHBY), AbbVie Inc (NYSE: ABBV), Amgen Inc (NYSE: AMGN), Sanofi (NYSE: SNY), Merck & Co (NYSE: MRK) Inc, Novo Nordisk (NYSE: NVO), Novartis AG (NYSE: NVS), Pfizer Inc (NYSE: PFE), AstraZeneca (NYSE: AZN), Bristol Myers Squibb (NYSE: BMY), Regeneron Pharmaceuticals Inc (NYSE: REGN), Gilead Sciences Inc (NYSE: GILD), Boehringer Ingelheim International GmbH., Genentech Inc, Biogen (NYSE: BIIB), Bluebird Bio Inc (NYSE: BLUE), Janssen Global Services LLC (NYSE: JNJ), Cellitron Group and others.
- Biologics Market By Product Type (Cell-Based Biologics, Gene-Based Biologics, Monoclonal Antibodies, Vaccines, Recombinant Proteins, And Others)
- Biologics Market By Application (Oncology, Immunology, Infectious Diseases, Neurological Diseases, And Others)
- Biologics Market By Manufacturing Type (In-House And Outsourced)
- Porter’s Five Forces Analysis, Product Profiles, Cases Studies, KOL’s Views, a0nd Analyst’s View
Table of content
- Report Introduction
- Executive Summary
- Regulatory and Patent Analysis
- Key Factors Analysis
- Porter’s Five Forces Analysis
- COVID-19 Impact Analysis
- Biologics Market Layout
- Biologics Market Global Company Share Analysis – Key 3-5 Companies
- Biologics Market Company and Product Profiles
- KOL Views
- Project Approach
- About DelveInsight
- Disclaimer & Contact Us
For more details about the market share of Biologics, just click here @ Biologic Market Share
Key Takeaways from the Biologics Market Report Study
- Market size analysis for current biologics market size (2020), and market forecast for 5 years (2021-2026)
- The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the biologics market.
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened in the last 3 years
- Key companies dominating the global biologics market.
- Various opportunities are available for the other competitor in the biologics market space.
- What are the top-performing segments in 2020? How these segments will perform in 2026.
- Which are the top-performing regions and countries in the current biologics market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for biologics market growth in the coming future?
Are you interested to get information about the Biologics market? If yes, you are just one click away @ Global Biologic Market Size
Related Reports
Active Pharmaceutical Ingredients Market
DelveInsight’s Active Pharmaceutical Ingredients Market Insights, Competitive Landscape, and Market Forecast-2027 report delivers an in-depth understanding of Active Pharmaceutical Ingredients and Competitive Landscape analysis. Key players involved in this market are Aurobindo Pharma, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Novartis AG, BASF SE, Boehringer Ingelheim GmbH, Dr. Reddy’s Laboratories Ltd, Lupin Ltd, Viatris, Sun Pharmaceutical Industries Ltd, Merck KGaA, AbbVie Inc., Bristol Myers-Squibb Company, Cipla Inc, Divi’s Laboratories Limited, GlaxoSmithKline plc, Albemarle Corporation, Orion Corporation, Fidia Farmaceutici s.p.a., AstraZeneca, and others.
DelveInsight’s Biosimilars Market Insights, Competitive Landscape, and Market Forecast-2027 report delivers an in-depth understanding of Biosimilars and Competitive Landscape analysis. Key players involved in this market are Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Amgen, Inc., Eli Lilly and Company, Novartis AG, Bioeq AG, Fresenius SE & Co. KGaA, STADA Arzneimittel AG, Gedeon Richter PLC, Celltrion Healthcare Co., Ltd., Samsung Bioepis. (Samsung Biologics), Coherus BioSciences, Viatris Inc., Shanghai Henlius Biotech, Inc., Biocon Limited, Biocad, mAbxience, Fujifilm Kyowa Kirin Biologics Co., Ltd., Alvotech, Sanofi, Senju Pharmaceutical Co., Ltd., and others.
DelveInsight’s Stem Cell Market Insights, Competitive Landscape, and Market Forecast-2027 report deliver an in-depth understanding of Stem Cell and Competitive Landscape analysis. Key players involved in this market include Osiris Therapeutics, Inc. (Smith+Nephew Inc.), MEDIPOST Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., JCR Pharmaceuticals Co. Ltd., NuVasive®, Inc., Stempeutics Research Pvt Ltd., Bristol-Myers Squibb Company, Organogenesis Inc., Takeda Pharmaceutical Company Limited, CHIESI SAS, Tegoscience, Bio solution Co., Ltd., CORESTEM, Inc., CO.DON, NIPRO, and others.
Related Blogs by DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get in touch with our team to get more detailed insights into how the MedTech Market is expected to evolve in the coming years and to formulate innovative business solutions, at MedTech Consulting Solutions
Contact Us
Yash Bhardwaj
info@delveinsight.com
+1(919)321-6187